

Beverley Shea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6073894/publications.pdf>

Version: 2024-02-01

86

papers

8,471

citations

257429

24

h-index

56717

83

g-index

93

all docs

93

docs citations

93

times ranked

11983

citing authors

#	ARTICLE	IF	CITATIONS
1	Bibliometric study of "overviews of systematic reviews"™ of health interventions: Evaluation of prevalence, citation and journal impact factor. Research Synthesis Methods, 2022, 13, 109-120.	8.7	12
2	A new taxonomy was developed for overlap across 'overviews of systematic reviews': A meta-research study of research waste. Research Synthesis Methods, 2022, 13, 315-329.	8.7	10
3	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2022, 55, 152021.	3.4	2
4	Facilitating and supporting the engagement of patients, families and caregivers in research: the "Ottawa model" for patient engagement in research. Research Involvement and Engagement, 2022, 8, .	2.9	9
5	Identification of outcomes in clinical studies of interventions for venous thromboembolism in non-pregnant adults: A scoping review. Journal of Thrombosis and Haemostasis, 2022, 20, 2313-2322.	3.8	7
6	Outcomes Measured in Polymyalgia Rheumatica and Measurement Properties of Instruments Considered for the OMERACT Core Outcome Set: A Systematic Review. Journal of Rheumatology, 2021, 48, 883-893.	2.0	13
7	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.9	6
8	Effectiveness of person- and family-centred care transition interventions on patient-oriented outcomes: A systematic review. Nursing Open, 2021, 8, 721-754.	2.4	13
9	Screening for depression in children and adolescents: a protocol for a systematic review update. Systematic Reviews, 2021, 10, 24.	5.3	11
10	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. Journal of Rheumatology, 2021, 48, 1480-1487.	2.0	0
11	Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 650-654.	3.4	8
12	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 607-617.	3.4	3
13	Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 655-660.	3.4	5
14	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 640-643.	3.4	8
15	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism, 2021, 51, 1320-1330.	3.4	25
16	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	3.4	7
17	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 946-950.	3.4	11
18	Development of an extension of the OMERACT Summary of Measurement Properties table to capture equity considerations: SOMP-Equity. Seminars in Arthritis and Rheumatism, 2021, 51, 1300-1310.	3.4	4

#	ARTICLE	IF	CITATIONS
19	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 1113-1116.	3.4	4
20	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Seminars in Arthritis and Rheumatism, 2021, 51, 1108-1112.	3.4	8
21	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. Seminars in Arthritis and Rheumatism, 2021, 51, 1139-1145.	3.4	8
22	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 1134-1138.	3.4	4
23	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. Seminars in Arthritis and Rheumatism, 2021, 51, 1370-1377.	3.4	3
24	“There was no preamble”: Comparing the Transition from Hospital to Home in Different Care Settings. Canadian Journal on Aging, 2021, 40, 282-292.	1.1	0
25	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 1378-1385.	3.4	3
26	When to replicate systematic reviews of interventions: consensus checklist. BMJ, The, 2020, 370, m2864.	6.0	58
27	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. Journal of Rheumatology, 2020, 47, 1379-1384.	2.0	10
28	PROTOCOL: When and how to replicate systematic reviews. Campbell Systematic Reviews, 2020, 16, e1087.	3.0	4
29	Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2020, 50, 719-727.	3.4	10
30	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. Annals of the Rheumatic Diseases, 2020, 79, 1269-1276.	0.9	3
31	Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s) factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC). Systematic Reviews, 2020, 9, 20.	5.3	11
32	Combination Tests in the Diagnosis of Chronic Periprosthetic Joint Infection. Journal of Bone and Joint Surgery - Series A, 2020, 102, 114-124.	3.0	8
33	Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. BMJ Open, 2020, 10, e040122.	1.9	1
34	Patients’ and caregivers’ perspectives on factors that influence understanding of and adherence to hospital discharge instructions: a qualitative study. CMAJ Open, 2019, 7, E478-E483.	2.4	8
35	A Systematic Review and Meta-analysis of Nonpharmacologic-based Interventions for Aortic Stiffness in End-Stage Renal Disease. Kidney International Reports, 2019, 4, 1109-1121.	0.8	6
36	Effectiveness of stop smoking interventions among adults: protocol for an overview of systematic reviews and an updated systematic review. Systematic Reviews, 2019, 8, 28.	5.3	16

#	ARTICLE	IF	CITATIONS
37	Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Systematic Reviews, 2019, 8, 27.	5.3	30
38	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
39	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. Journal of Rheumatology, 2019, 46, 1360-1364.	2.0	5
40	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	2.0	61
41	The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. Journal of Rheumatology, 2019, 46, 969-975.	2.0	25
42	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	2.0	8
43	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201.	2.0	24
44	Patients' experience of shoulder disorders: a systematic review of qualitative studies for the OMERACT Shoulder Core Domain Set. Rheumatology, 2019, 58, 1410-1421.	1.9	36
45	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. Journal of Rheumatology, 2019, 46, 976-980.	2.0	25
46	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. Journal of Rheumatology, 2019, 46, 1409-1414.	2.0	14
47	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	2.0	36
48	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. Journal of Rheumatology, 2019, 46, 1168-1172.	2.0	8
49	Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development. Journal of Rheumatology, 2019, 46, 1041-1046.	2.0	21
50	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	2.0	97
51	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	2.0	65
52	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology, 2019, 46, 1006-1013.	2.0	34
53	Diagnostic Accuracy of Serum, Synovial, and Tissue Testing for Chronic Periprosthetic Joint Infection After Hip and Knee Replacements. Journal of Bone and Joint Surgery - Series A, 2019, 101, 635-649.	3.0	60
54	Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. Journal of Rheumatology, 2019, 46, 106-111.	2.0	25

#	ARTICLE	IF	CITATIONS
55	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019, 46, 981-989.	2.0	82
56	Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e025059.	1.9	10
57	Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review. <i>BMJ Open</i> , 2018, 8, e023902.	1.9	5
58	What is the impact of sensory practices on the quality of life of long-term care residents? A mixed-methods systematic review protocol. <i>Systematic Reviews</i> , 2018, 7, 115.	5.3	4
59	Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. <i>Transfusion</i> , 2018, 58, 2437-2452.	1.6	17
60	The prevalence of patient engagement in published trials: a systematic review. <i>Research Involvement and Engagement</i> , 2018, 4, 17.	2.9	101
61	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1727-1733.	2.0	12
62	GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist. <i>Journal of Clinical Epidemiology</i> , 2017, 90, 68-75.	5.0	46
63	Potential predatory and legitimate biomedical journals: can you tell the difference? A cross-sectional comparison. <i>BMC Medicine</i> , 2017, 15, 28.	5.5	266
64	Introduction. <i>Journal of Rheumatology</i> , 2017, 44, 1511-1514.	2.0	0
65	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017, 44, 1515-1521.	2.0	33
66	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	2.0	21
67	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	2.0	27
68	Considerations and guidance in designing equity-relevant clinical trials. <i>International Journal for Equity in Health</i> , 2017, 16, 93.	3.5	44
69	AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. <i>BMJ: British Medical Journal</i> , 2017, 358, j4008.	2.3	4,681
70	Effectiveness of person- and family-centered care transition interventions: a systematic review protocol. <i>Systematic Reviews</i> , 2017, 6, 158.	5.3	16
71	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	2.0	25
72	The impact of intervention strategies that target arterial stiffness in end-stage renal disease: a systematic review protocol. <i>Systematic Reviews</i> , 2016, 5, 118.	5.3	6

#	ARTICLE	IF	CITATIONS
73	GRADE: Assessing the quality of evidence in environmental and occupational health. Environment International, 2016, 92-93, 611-616.	10.0	194
74	ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology, 2016, 69, 225-234.	5.0	1,204
75	A protocol for a systematic review of the diagnostic accuracy of blood markers, synovial fluid, and tissue testing in periprosthetic joint infections (PJI). Systematic Reviews, 2015, 4, 148.	5.3	27
76	Food Supplementation for Improving the Physical and Psychosocial Health of Socioeconomically Disadvantaged Children Aged Three Months to Five Years: A Systematic Review. Campbell Systematic Reviews, 2015, 11, 1-226.	3.0	10
77	Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 1049-1060.	2.0	112
78	Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Research Synthesis Methods, 2013, 4, 49-62.	8.7	187
79	Philadelphia Panel Evidence-Based Clinical Practice Guidelines on Selected Rehabilitation Interventions for Neck Pain. Physical Therapy, 2001, , .	2.4	1
80	Philadelphia Panel Evidence-Based Clinical Practice Guidelines on Selected Rehabilitation Interventions for Low Back Pain. Physical Therapy, 2001, , .	2.4	3
81	Philadelphia Panel Evidence-Based Clinical Practice Guidelines on Selected Rehabilitation Interventions for Shoulder Pain. Physical Therapy, 2001, , .	2.4	1
82	Philadelphia Panel Evidence-Based Clinical Practice Guidelines on Selected Rehabilitation Interventions: Overview and Methodology. Physical Therapy, 2001, , .	2.4	17
83	Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 1841-1847.	6.7	254
84	Do silicone breast implants cause rheumatologic disorders?: A systematic review for a Court-Appointed National Science Panel. Arthritis and Rheumatism, 2001, 44, 2477-2484.	6.7	119
85	Sulfasalazine for treating rheumatoid arthritis. The Cochrane Library, 1998, , CD000958.	2.8	35
86	Vitamin D with or without calcium for treating osteoporosis in postmenopausal women. The Cochrane Library, 1997, , .	2.8	0